Back to top
more

Alector (ALEC)

(Delayed Data from NSDQ)

$5.75 USD

5.75
634,576

+0.11 (1.95%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $5.74 -0.01 (-0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Alector (ALEC) delivered earnings and revenue surprises of 18.87% and 6.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?

by Zacks Equity Research

Ascendis Pharma (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Alector (ALEC) delivered earnings and revenue surprises of 18.37% and 5.94%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Akoya Biosciences (AKYA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Akoya (AKYA) delivered earnings and revenue surprises of 0% and 1.89%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?

by Zacks Equity Research

Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alector (ALEC) delivered earnings and revenue surprises of 20.83% and 8.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline

by Zacks Equity Research

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength?

by Zacks Equity Research

Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Alector (ALEC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts Think Alector (ALEC) Could Surge 142.53%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 142.5% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for Alector (ALEC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study

by Zacks Equity Research

Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.

UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why

by Zacks Equity Research

This jump in UroGen's (URGN) stock price is attributable to positive data from two late-stage studies on bladder cancer therapy. An FDA filing for the candidate is expected next year.

Wall Street Analysts Believe Alector (ALEC) Could Rally 102%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 102% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Alector (ALEC) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Alector (ALEC) delivered earnings and revenue surprises of 102.47% and 1,450.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Does Alector (ALEC) Have the Potential to Rally 86.38% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at an 86.4% upside potential for Alector (ALEC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alector (ALEC) delivered earnings and revenue surprises of 26.67% and 79.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in Alector (ALEC) Stock?

by Zacks Equity Research

Investors need to pay close attention to Alector (ALEC) stock based on the movements in the options market lately.

Repare Therapeutics Inc. (RPTX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -2.74% and 84.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Merus N.V. (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alector (ALEC) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Alector (ALEC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.